uPAR(+) extracellular vesicles: a robust biomarker of resistance to checkpoint inhibitor immunotherapy in metastatic melanoma patients

BACKGROUND: Emerging evidence has highlighted the importance of extracellular vesicle (EV)-based biomarkers of resistance to immunotherapy with checkpoint inhibitors in metastatic melanoma. Considering the tumor-promoting implications of urokinase-type plasminogen activator receptor (uPAR) signaling...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Porcelli, Letizia, Guida, Michele, De Summa, Simona, Di Fonte, Roberta, De Risi, Ivana, Garofoli, Marianna, Caputo, Mariapia, Negri, Antonio, Strippoli, Sabino, Serratì, Simona, Azzariti, Amalia
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2021
Assuntos:
Immunotherapy Biomarkers
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8112420/
https://ncbi.nlm.nih.gov/pubmed/33972390
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2021-002372
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados